個別化医療の世界市場規模：製品別、エンドユーザー別、地域別、範囲および予測

個別化医療の市場規模と予測

個別化医療市場規模は、2024年に1,302億3,000万米ドルと評価され、2024年～2031年の間に10.67％のCAGRで成長する見込みで、2031年には2,725億9,000万米ドルに達すると予測されます。個別化医療（精密医療とも呼ばれる）は、予防、診断、治療といったヘルスケアの意思決定を、個人の特定の遺伝子構成やその他の個人的特徴に合わせて調整する医療アプローチです。この治療法は、遺伝子検査やバイオマーカーから得られたデータを用いて治療法を最適化し、患者が最も効果的で副作用の少ない医薬品を受けられるようにするものです。

個別化医療の応用には、遺伝子プロファイルに基づいて個人に最適な薬剤と投与量を決定する薬理ゲノミクス、独自の分子標的に焦点を当てた特定のがんに対する標的療法、特定の疾患に対する遺伝的素因に基づいた予防対策などがあります。

さらに、個別化医療は、より正確で専門的な治療を提供することによって患者の転帰を改善するために、ヒトゲノム計画などのプログラムから得られた高度な技術やデータを利用します。

個別化医療の世界市場力学

個別化医療市場を形成している主な市場力学

主な市場促進要因

がんと遺伝性疾患の有病率の増加：

がんと遺伝性疾患の有病率の増加は、個別化医療技術の必要性を押し上げています。世界保健機関（WHO）によると、がんは世界最大の死因であり、2020年には約1,000万人が死亡します。国際がん研究機関（IARC）は、2040年には世界のがん患者数が2020年比47％増の2,840万人に達すると予測しています。がん負担の増加は、標的治療や個別化治療アプローチの開発を促進しています。

ゲノムシーケンス技術の進歩：

遺伝子配列決定技術の急速な進歩により、オーダーメイド医療がより身近で安価なものとなっています。National Human Genome Research Instituteによると、ヒトゲノムの塩基配列決定にかかる費用は、2001年の約1億米ドルから2021年には1,000ドル未満へと大幅に減少しています。この大幅なコスト削減により、臨床現場での遺伝子検査の利用が増加し、個別化治療の選択肢が可能になった。

精密医療イニシアティブへの投資の増加：

政府や企業は、精密医療の研究と実施への投資を増やしています。例えば、米国国立衛生研究所（NIH）は、All of Us研究開発プログラムを開発し、100万人以上の米国人からデータを収集し、研究を加速させ、健康転帰を改善することを意図しています。2023年9月現在、このプログラムは74万6千人以上を登録し、48万2千人以上がゲノム解析のためにバイオサンプルを提出しています。この大規模な試みは、個別化医療のアプローチ拡大への関心の高まりを反映しています。

主な課題

ヘルスケア格差：

個別化医療は、主に欧州の集団から得られたゲノムデータに基づいているため、さまざまな人種や民族のグループに対する治療効果の偏りが生じています。この過小評価は、様々な背景を持つ患者の反応を確実に予測できないアルゴリズムにつながり、既存のヘルスケア格差を拡大します。

規制監督：

個別化医療技術が進歩し、従来の治療と比較してその安全性と有効性を評価するためには、規制機関による新たな基準の開発が必要です。これには、遺伝子やバイオマーカーのデータを臨床診療に統合するためのガイドラインの開発も含まれます。このような技術革新の臨床効果と費用対効果を評価するための確立された手順が存在しないことは、その承認と広範な受容の妨げとなり、この分野の進歩を制限しています。

主要動向：

ゲノム診断と標的治療の統合：

病院は、こうした最先端技術の利用頻度が高まるにつれて、患者固有のDNAプロファイルに基づいた個別の治療計画を提供できるようになった。この動向は、医療介入の精度を高め、特定の腫瘍特性に合わせた投薬が可能ながんなど、より効果的な疾病管理を可能にし、最終的に患者の転帰と満足度を高める。

デジタル・ヘルス・ソリューションへの投資の拡大：

遠隔医療、モバイルヘルスアプリ、ウェアラブルデバイスの登場により、患者の健康データの継続的なモニタリングが可能になり、治療プログラムをリアルタイムで変更できるようになった。これらのテクノロジーは、患者の健康状態や治療反応に関する情報を提供することで患者に力を与え、ヘルスケアへのより協力的なアプローチを促進し、個別化された治療レジメンへのアドヒアランスを向上させる。

個別化された栄養とウェルネス：

オーダーメイドの栄養とウェルネスが重視されるようになり、個別化医療市場の重要な分野として浮上しています。顧客の健康意識が高まるにつれて、特定の遺伝的プロファイルや健康上の懸念に対応する個別化栄養レジメンや補助食品に対するニーズが高まっています。この動向は、食事が健康や疾病管理にどのように影響するかについてのより包括的な理解を反映しており、その結果、特定の健康上の懸念に対処しながら全体的な健康を促進する独創的なソリューションが生まれています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 個別化医療市場：製品タイプ別

• 個別化医療診断薬
• 個別化医療治療薬

第5章 個別化医療市場：用途別

• 腫瘍学
• 神経学
• 循環器
• その他の用途

第6章 個別化医療市場：エンドユーザー別

• 病院およびクリニック
• 研究機関および研究所
• 製薬・バイオテクノロジー企業
• 患者

第7章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Roche
• Illumina
• Novartis
• Amgen
• Merck & Co., Inc.
• Thermo Fisher Scientific
• QIAGEN
• Myriad Genetics
• Exact Sciences Corporation
• IQVIA
• Syneos Health

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Personalized Medicine Market Size and Forecast

Personalized Medicine Market size was valued at USD 130.23 Billion in 2024 and is projected to reach USD 272.59 Billion by 2031 , growing at a CAGR of 10.67% from 2024 to 2031. Personalized medicine, also known as precision medicine, is a medical approach that tailors healthcare decisions-such as prevention, diagnosis, and treatment-to an individual's specific genetic composition and other personal traits. This practice uses data from genetic testing and biomarkers to optimize therapeutic actions, ensuring that patients receive the most effective medicines with the fewest negative effects.

Personalized medicine applications include pharmacogenomics, which helps determine the best medications and dosages for individuals based on their genetic profiles; targeted therapies for specific cancers that focus on unique molecular targets; and preventive measures informed by genetic predisposition to certain diseases.

Furthermore, personalized medicine uses advanced technologies and data from programs such as the Human Genome Project to improve patient outcomes by providing more precise and specialized treatment

Global Personalized Medicine Market Dynamics

The key market dynamics that are shaping the personalized medicine market include:

Key Market Drivers

Increasing Prevalence of Cancer and Genetic Disorders:

The increased prevalence of cancer and genetic disorders is pushing the need for personalized medicine techniques. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, accounting for approximately 10 million deaths in 2020. The International Agency for Research on Cancer (IARC) predicts that the worldwide cancer burden will reach 28.4 million cases in 2040, up 47% from 2020. The increasing cancer burden is driving the development of targeted treatments and personalized treatment approaches.

Advancements in Genomic Sequencing Technologies:

Rapid advancements in genetic sequencing technology are making customized medicine more accessible and inexpensive. According to the National Human Genome Research Institute, the cost of sequencing a human genome has decreased drastically, from approximately USD 100 Million in 2001 to less than $1,000 in 2021. This large cost reduction has resulted in increased usage of genetic testing in clinical settings, allowing for personalized treatment options.

Growing Investment in Precision Medicine Initiatives:

Governments and corporate entities are increasing their investments in precision medicine research and implementation. For example, the National Institutes of Health (NIH) in the United States developed the All of Us Research Program, which intends to collect data from one million or more Americans to speed up research and improve health outcomes. As of September 2023, the initiative had registered over 746,000 people, with over 482,000 submitting biosamples for genomic analysis. This large-scale endeavor reflects the growing interest in expanding personalized medicine approaches.

Key Challenges:

Healthcare Disparities:

Personalized medicine is based primarily on genomic data from European populations, which leads to therapeutic efficacy biases for varied racial and ethnic groups. This underrepresentation leads to algorithms that do not reliably anticipate reactions from patients from various backgrounds, increasing existing healthcare disparities.

Regulatory Oversight:

The development of new standards by regulatory bodies is necessary as personalized medicine technologies progress to assess their safety and effectiveness in comparison to conventional treatments. This includes developing guidelines for integrating genetic and biomarker data into clinical practice. The absence of established procedures for evaluating the clinical and cost-effectiveness of these innovations hampers their approval and widespread acceptance, limiting progress in this field.

Key Trends:

Integration of Genomic Diagnostics and Targeted Therapies:

Hospitals can now offer individualized treatment plans based on patient's unique DNA profiles as they use these cutting-edge technologies more frequently. This trend increases the accuracy of medical interventions, allowing for more effective disease management, such as cancer, where medications can be tailored to specific tumor characteristics, ultimately increasing patient outcomes and satisfaction.

Growing Investment in Digital Health Solutions:

The advent of telemedicine, mobile health apps, and wearable devices has enabled continuous monitoring of patient health data, allowing for real-time alterations to treatment programs. These technologies empower patients by providing them with information on their health and treatment responses, promoting a more collaborative approach to healthcare and increasing adherence to individualized treatment regimens.

Personalized Nutrition and Wellness:

There is a growing emphasis on tailored nutrition and wellness, which is emerging as a crucial area of the personalized medicine market. As customers become more health-conscious, there is a growing need for personalized dietary regimens and supplements that address specific genetic profiles and health concerns. This trend reflects a more comprehensive understanding of how diet affects health and illness management, resulting in creative solutions that promote overall well-being while addressing specific health concerns.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Personalized Medicine Market Regional Analysis

Here is a more detailed regional analysis of the personalized medicine market:

Asia Pacific:

According to Verified Market Research, the Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. The increased frequency of cancer and genetic illnesses in the Asia Pacific region is driving demand for personalized medical strategies. According to the International Agency for Research on Cancer (IARC), Asia accounted for over half of all new cancer cases worldwide in 2020, with an estimated 8.9 million new cases. According to the IARC, by 2040, this number will climb to around 14.5 million new cases per year in Asia. This rising cancer burden is driving investments in genetic research and personalized treatment strategies throughout the region.

Furthermore, the Asia Pacific region's population is rapidly growing and aging, creating demand for personalized healthcare solutions. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's population is predicted to grow from 4.3 billion in 2020 to 4.7 billion in 2050. Also, the population aged 65 and up is expected to more than quadruple, from 395 million in 2020 to 956 million by 2050. This generational transition is increasing the demand for more tailored and effective medical treatments, hence boosting the personalized medicine market.

North America:

North America is estimated to dominate the personalized medicine market during the forecast period. North America, particularly the United States, has a significant burden of chronic diseases that can be addressed using personalized medicine approaches. According to the Centers for Disease Control and Prevention (CDC), six out of every ten persons in the United States have a chronic disease, with four out of ten having two or more. In 2019, around 37.3 million Americans (11.3% of the total population) had diabetes. The rising frequency of chronic diseases creates a desire for more targeted and effective therapies provided by personalized medicine.

Furthermore, North America has a well-developed healthcare infrastructure that easily accepts new technology, helping the adoption of personalized medicine. According to the US Food and Drug Administration (FDA), the number of approved personalized medicines has increased significantly. In 2022, personalized medicines accounted for 25% of all new drug approvals, up from 5% in 2005. This trend reflects the region's ability to translate research into practical applications, hence boosting the expansion of the personalized medicine market.

Global Personalized Medicine Market: Segmentation Analysis

The Personalized Medicine Market is segmented based on Product, End-User, and Geography.

Personalized Medicine Market, By Product

• Personalized Medicine Diagnostics
• Personalized Medicine Therapeutics
• Personalized Medical Care
• Personalized Nutrition & Wellness

Based on Product, the market is segmented into Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, and Personalized Nutrition & Wellness. The personalized medicine diagnostics segment is estimated to dominate the personalized medicine market. This dominance is primarily driven by the growing demand for improved diagnostic tools capable of detecting genetic variants and biomarkers associated with a variety of disorders, including cancer. The rising frequency of chronic diseases needs more precise diagnostic procedures, resulting in increased investment in genetic testing and direct-to-consumer diagnostics.

Personalized Medicine Market, By End-User

• Hospitals
• Diagnostic Centers
• Research & Academic Institutes
• Others

Based on End-User, the Personalized Medicine Market is divided into Hospitals, Diagnostic Centers, Research & Academic Institutes, and Others. The hospital segment is estimated to dominate the market over the forecast period due to hospitals' crucial role as key providers of personalized healthcare services, which incorporate genomic diagnostics and tailored medicines into patient care. Their specialized facilities and skills enable them to efficiently implement innovative treatment approaches, thereby driving the expansion of personalized medicine and determining its future clinical practice.

Personalized Medicine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Personalized Medicine Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate the market during the forecasted period due to the region's superior healthcare infrastructure, significant R&D investments, and high rates of chronic diseases such as cancer and diabetes. Furthermore, the substantial presence of top biotech and pharmaceutical businesses promotes innovation and acceptance of customized medicine solutions, firmly establishing North America as a market leader.

Key Players

• The "Personalized Medicine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Roche, Illumina, Novartis, Amgen, Merck & Co., Inc., Thermo Fisher Scientific, QIAGEN, Myriad Genetics, Exact Sciences Corporation, IQVIA, and Syneos Health.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Personalized Medicine Market Recent Developments
• In September 2023, Agilent Technologies and Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) signed a Memorandum of Understanding (MOU) to advance gene and cell therapy over the next three years.
• In July 2023, Pillar Biosciences and Illumina announced a strategic alliance to commercialize Pillar's range of oncology assays globally. Completing the agreement will provide unprecedented Next-Generation Sequencing (NGS) technologies, increasing patient access to individualized cancer treatment options.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Personalized Medicine Market, By Product Type

• Individualized Medical Care Diagnostics
• Individualized Medical Care Therapeutics

5. Personalized Medicine Market, By Application

• Oncology
• Neurology
• Cardiology
• Additional Uses

6. Personalized Medicine Market, By End User

• Hospitals and Clinics
• Research Institutions and Laboratories
• Pharmaceutical and Biotechnology Companies
• Patients

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Roche
• Illumina
• Novartis
• Amgen
• Merck & Co., Inc.
• Thermo Fisher Scientific
• QIAGEN
• Myriad Genetics
• Exact Sciences Corporation
• IQVIA
• Syneos Health

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References